Technology news website Re/code has revealed in a recent report that the much-rumored Apple iWatch wearable device - which will likely be unveiled by the company at its forthcoming September 9 event - will be price at approximately $400.
The price-tag being mulled by Apple for its iWatch smartwatch marks a continuation of the company's strategy to charge an exorbitant premium price for its products. In comparison to the project pricing of the iWatch, the currently-available smartwatches are mostly priced in the range of between $250 and $350.
Nonetheless, the premium price which Apple is expected to charge for its iWatch will probably be not much of an issue if the company comes up with a product that successfully amalgamates style with functionality.
Meanwhile, along with projecting the hefty $400 premium price at which Apple will likely sell its iWatch, the Re/code report also said - on the basis of details shared by unidentified sources - that the iWatch may possibly be released by Apple at different price points.
The iWatch will mark Apple's foray into the wearable devices arena; and is expected to hit the markets in 2015. The imminent launch of the iWatch is widely being considered the crucial event which is apparently required for making wearable devices mainstream.
There are a lot of things not going right at the IRS and mostly so when it comes to filing for Earned Income Tax Credits (EITC).
In December 2014, a report by Watchdog.org showed that that an audit by the IRS documented twenty four percent...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
In a blog post published on Wednesday, Twitter-owned...
A draft New York legislation proposes the use of a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).